Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus abiraterone in metastatic castration-resistant prostate cancer after docetaxel
NL-OMON40368Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olaparib and abiraterone in prostate cancer (PCa) (7 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Dose-limiting toxicities. Planned start Mar 2014; status: withdrawn.
02
Drugs
olaparibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON40368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40368.